Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update

Immix Biopharma, Inc. (NASDAQ:IMMX) was the target of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 356,500 shares, a decline of 11.0% from the December 15th total of 400,500 shares. Based on an average trading volume of 165,700 shares, the days-to-cover ratio is presently 2.2 days. Currently, 2.2% of the shares of the company are short sold.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Immix Biopharma in a research note on Monday, January 6th.

Immix Biopharma Stock Performance

IMMX stock traded down $0.02 during trading on Friday, reaching $2.04. 121,030 shares of the company were exchanged, compared to its average volume of 140,296. The company has a market cap of $56.12 million, a P/E ratio of -2.40 and a beta of 0.27. Immix Biopharma has a 52-week low of $1.26 and a 52-week high of $5.73. The stock’s 50 day moving average price is $2.07 and its 200 day moving average price is $1.95.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.08). As a group, equities research analysts forecast that Immix Biopharma will post -0.74 EPS for the current year.

Hedge Funds Weigh In On Immix Biopharma

Institutional investors have recently modified their holdings of the company. Invst LLC acquired a new position in Immix Biopharma during the second quarter worth approximately $57,000. FNY Investment Advisers LLC acquired a new position in Immix Biopharma during the fourth quarter worth approximately $63,000. Finally, Geode Capital Management LLC increased its position in Immix Biopharma by 5.6% during the third quarter. Geode Capital Management LLC now owns 150,082 shares of the company’s stock worth $224,000 after purchasing an additional 7,954 shares during the last quarter. Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.